Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Expression of oestrogen receptor-beta in apocrine carcinomas of the breast.

Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, Hosoi T, Yoshimura N, Harada N, Younes M, Sakamoto G.

Histopathology. 2007 Mar;50(4):425-33.

PMID:
17448017
2.

Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.

Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G.

Histopathology. 2005 Aug;47(2):195-201.

PMID:
16045781
3.

Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast.

Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K, Sakamoto G.

APMIS. 2008 Oct;116(10):923-30. doi: 10.1111/j.1600-0463.2008.01122.x.

PMID:
19132986
4.

Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.

Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P.

Hum Pathol. 2008 Mar;39(3):386-92. doi: 10.1016/j.humpath.2007.07.007. Epub 2008 Jan 9.

PMID:
18187183
5.
6.

Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status.

Honma N, Sakamoto G, Akiyama F, Esaki Y, Sawabe M, Arai T, Hosoi T, Harada N, Younes M, Takubo K.

Histopathology. 2003 Feb;42(2):120-7.

PMID:
12558743
7.

Histological and immunohistochemical analysis of apocrine breast carcinoma.

Matsuo K, Fukutomi T, Hasegawa T, Akashi-Tanaka S, Nanasawa T, Tsuda H.

Breast Cancer. 2002;9(1):43-9.

PMID:
12196721
8.

Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.

Lin Fde M, Pincerato KM, Bacchi CE, Baracat EC, Carvalho FM.

J Clin Pathol. 2012 Jan;65(1):64-8. doi: 10.1136/jclinpath-2011-200318. Epub 2011 Oct 29.

PMID:
22039288
9.

Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.

Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G.

Mod Pathol. 2001 Aug;14(8):768-76.

10.

Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.

Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L, Jackisch C.

Oncol Rep. 2004 Oct;12(4):695-9.

PMID:
15375487
11.

Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.

Kaya H, Bozkurt SU, Erbarut I, Djamgoz MB.

Pathol Res Pract. 2008;204(6):367-71. doi: 10.1016/j.prp.2008.01.012. Epub 2008 Mar 14.

PMID:
18342452
12.

17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.

Oduwole OO, Li Y, Isomaa VV, Mäntyniemi A, Pulkka AE, Soini Y, Vihko PT.

Cancer Res. 2004 Oct 15;64(20):7604-9.

14.

Analysis of estrogen receptor alpha and beta in endometrial carcinomas: correlation with ER beta and clinicopathologic findings in 45 cases.

Utsunomiya H, Suzuki T, Harada N, Ito K, Matsuzaki S, Konno R, Sato S, Yajima A, Sasano H.

Int J Gynecol Pathol. 2000 Oct;19(4):335-41.

PMID:
11109162
16.

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H.

Cancer. 2003 Aug 15;98(4):703-11.

17.

Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.

Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ.

Br J Surg. 2005 Apr;92(4):429-34.

PMID:
15736216
18.

Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.

Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.

Histopathology. 2007 Jun;50(7):866-74.

PMID:
17543076
19.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
20.

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G.

J Clin Oncol. 2008 Aug 1;26(22):3727-34. doi: 10.1200/JCO.2007.14.2968.

PMID:
18669459

Supplemental Content

Support Center